ICON expects market conditions to remain similar through year-end, assuming persistent cancellation rates and mixed timing on biotech conversions. The company raised its full year revenue guidance to ...

Full-year revenue guidance was updated to a new range of $7.85 billion at the low end and $8.15 billion at the high end, "increasing the midpoint to $8 billion." The full-year adjusted earnings per ...

CRO giant Icon ($ICLR) charted double-digit revenue growth in the third quarter, chugging toward its best-ever year and lifting its earnings projections in the ...

Icon has been hit hard by the disruptions from the global pandemic, and it’s starting to show up in the balance sheet. The CRO, based in Ireland, said in its second-quarter financials that revenue was ...

Earnings Call Insights: ICON Public Limited Company (ICLR) Q2 2025 Full-year revenue guidance was updated to a new range of $7.85 billion at the low end and $8.15 billion at the high end, "increasing ...

Earnings Call Insights: ICON Public Limited Company (ICLR) Q3 2025 Steven Cutler reflected on his tenure, noting ICON's growth from 8,500 to 40,000 employees and its rise in industry ranking. He ...